iMDx develops molecular diagnostic tests for transplanted organ rejection and sells them to hospitals, transplant centers and labs. IMDX reports earnings on Mon, Nov 9, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 24 | LUCID CAPITAL MARKETS | Initiated | Buy | |
| Aug 18 | Needham | Reiterated | Buy |
Seasonality
How IMDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in IMDX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMDX is in one of them and how their past IMDX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMDX in an article yet. Here's the latest on the wider market.
About Insight Molecular Diagnostics
iMDx is a diagnostics company based in Nashville, Tennessee. Its main focus is molecular tests that help monitor whether a transplanted organ is being rejected, sold under the GraftAssure name. The test kits are meant for hospitals, transplant centers and labs to run in their own facilities, and research kits are offered to research laboratories. The company also runs a clinical lab in Franklin, Tennessee, and provides assay development and testing services to life sciences and biotechnology companies.
- Headquarters
- Nashville, TN